Organization
R&D Department, Zai Lab (Shanghai) Co., Ltd
1 abstract
Abstract
Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors (GIST) as ≥4th line therapy: Long-term update from a single-arm, phase 2 trial.Org: Peking University Cancer Hospital & Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Fujian Medical University Union Hospital, The First Affiliated Hospital of Chongqing Medical University, Fudan University Shanghai Cancer Center,